2023 FDA approvals: unprecedented volume at moderate value
Nat Rev Drug Discov
.
2024 Feb;23(2):98.
doi: 10.1038/d41573-024-00011-9.
Authors
Mathias Baedeker
,
Michael S Ringel
,
Clemens C Möller
PMID:
38233681
DOI:
10.1038/d41573-024-00011-9
No abstract available
Publication types
News
MeSH terms
Antineoplastic Agents*
Drug Approval
Humans
United States
United States Food and Drug Administration
Substances
Antineoplastic Agents